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Abstract: Poorly controlled diabetes mellitus
(DM) is associated with the development of
long-term micro- and macro-vascular
complications. The predominant focus of
anti-diabetic therapy has been on lowering
glycosylated haemoglobin levels, with a strong
emphasis on fasting plasma glucose (particularly
in Type 2 DM). There is considerable evidence
indicating that post-meal hyperglycaemic levels
are independently associated with higher risks
of macro-vascular disease. Although some have
identified mechanisms which may account for
these observations, interventions which have
specifically targeted postprandial glucose rises
showed little or no effect in reducing
cardiovascular risk. Clinical experience and
some recent studies suggest acute
hyperglycaemia affects cognition and other
indicators of performance, equivalent to
impairment seen during hypoglycaemia. In
this brief report, we evaluated the published
studies and argue that acute hyperglycaemia is
worth investigating in relation to the real-life
implications. In summary, evidence exists
suggesting that acute hyperglycaemia may lead
to impaired cognitive performance and
productivity, but the relationship between
these effects and daily activities remains poorly
understood. Further research is required to
enhance our understanding of acute
hyperglycaemia in daily life. A better
appreciation of clinically relevant effects of
acute hyperglycaemia will allow us to
determine whether it needs to be addressed by
specific treatment.
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micro- and macro-vascular complications [1–6].
The predominant focus of anti-diabetic therapy
has been on lowering glycosylated haemoglobin
(HbA1c) levels, with a strong emphasis on
fasting plasma glucose [particularly in Type 2
DM (T2DM)]. There is considerable
epidemiological evidence indicating that
post-meal hyperglycaemic levels are
independently associated with higher risks of
macro-vascular disease [1]. Although some have
identified mechanisms which may account for
these observations, interventions which have
specifically targeted postprandial glucose rises
showed little or no effect in reducing
cardiovascular risk [7–10]. Clinical experience
and some recent studies [11–15] suggest acute
hyperglycaemia affects cognition and other
indicators of performance, equivalent to
impairment seen during hypoglycaemia. In
this brief report, we review the published
studies and argue that acute hyperglycaemia is
worth investigating in relation to the real-life
implications. Throughout this review the term
acute hyperglycaemia is mostly used, although
there is no clear definition available for this
term. As acute hyperglycaemia itself is not a
clear terminology other sources might refer to
this concept as (high) postprandial, glucose
spikes and post-challenge or short-term
hyperglycaemia/glucose. The analysis in this
article is based on previously conducted studies,
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
Acute hyperglycaemia causes symptoms of
increased thirst, urination, hunger and weight
loss [16]. Children with T1DM as well as their
parents describe negative effects of
hyperglycaemia including nausea, tiredness,
loss of temper, thirst, weakness and headaches
[11]. Although these physical symptoms might
go unnoticed acute hyperglycaemia could have
significant impact on cognitive performance and
mood. Recent experimental studies which have
investigated the relationship between high
blood glucose (BG) level and cognitive function
provide evidence of the potential effect of acute
hyperglycaemia [12–15]. Sommerfield et al. [15]
examined the effects of clamped hyperglycaemia
(297 mg/dL/16.5 mmol/L) on cognitive function
andmood states and found that in subjects blind
to their blood glucose, speed of information
processing, working memory and aspects of
attention were significantly impaired. Mood
was also adversely affected by acute
hyperglycaemia, including increased feelings of
agitation and anxiety, increased feelings of
tiredness and lethargy and decreased feelings of
happiness. Cox et al. [12] used a hand-held
computer which required participants with DM
to undertake a series of simple cognitive tests
before measuring their BG. They demonstrated
that at a BG[270 mg/dL (15 mmol/L), verbal
fluency and subtraction time slowed in
individuals with T1DM (significantly;
additional 1.7–3 s per subtraction). In persons
with T2DM all tests were significantly slowed
during hyperglycaemia ([270 mg/dL).
These changes have the potential to impair
patient well-being, daily activities and
productivity. For example, the performance of
DM patients at work or children taking tests
at school might be affected during a
hyperglycaemic episode. Individuals at work or
school often choose to maintain a relatively high
BG level to prevent hypoglycaemia [14]. Yet, if
short-term effects of acute hyperglycaemia
are significant, this strategy may be
counterproductive. Acute hyperglycaemia may
have additional (in)direct costs, reflected in
increased doctor’s visits and lost productivity.
It is difficult to be sure to what extent
impaired cognitive function measured by
experimental tests reflect real-life activities.
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Although the studies described above provide
valid evidence of the effect of hyperglycaemia
on cognitive function and mood, they were not
specifically designed to measure the direct
impact of these events on daily activities such
as driving and performance at school or during
tests. Importantly, in both the studies of
Sommerfield et al. [15] and Cox et al. [12],
individuals were blind to their BG at the time
their performance was measured. This increases
the likelihood that the measured alteration in
mood and impaired performance are a direct
result of the acute increase in BG. Furthermore,
the observation that impaired performance was
equivalent to that observed during (acute)
hypoglycaemia suggests that the changes
observed may be clinically relevant.
To establish the importance of acute rises in
BG, further (real-world) research is required, as
this evidence is currently unavailable. Further
research can establish whether acute
hyperglycaemia impairs daily activities such as
working, driving and school performance.
Studies should also explore the level of BG
above which performance is impaired to
determine the BG range which impairs
cognitive functioning. Published guidelines
propose that patients aim for BG values below
160 or 180 mg/dL to prevent long-term
complications but it is unclear if this threshold
also applies to the short-term effects [1].
Future research might involve the use of
driving simulators or ‘real-life’ examinations,
experimental approaches which have been used
in the study of hypoglycaemia and which have
provided important clinical guidance to both
professional caretakers and patients. Mood,
patient well-being, productivity and resource use
may also be assessed by patient-reported outcome
measures. Simultaneous BG levels can be
measured either by self-monitored blood glucose
(SMBG) or continuous glucose monitoring
(CGM). Most patients and their carers continue
to rely on SMBG, but its inability to identify
whether glucose levels are rising or falling means
that the information it provides is relatively
incomplete and it is difficult to compare data
across patients. SMBG is also unable to reliably
detect hyperglycaemic unawareness and
nocturnal hypoglycaemia compared to CGM.
CGM offers continuous glucose data with regular
intervals to adjust insulin therapy and to monitor
lifestyle intervention. As CGM measures the BG
value throughout the day it is more likely to
identify episodes of acute hyperglycaemia and the
time spent in a hyperglycaemic state [17]. In the
last few years, the accuracy, precision, stability,
reliability and availability of CGM is approaching
SMBGand laboratorymeasurements [18]. Subjects
should be blinded to their BG value, when
completing assignments and questionnaires, to
prevent outcomes to be negatively affected by
patient mood changes resulting from seeing a BG
value they regard as undesirable.
CONCLUSION
Evidence exists suggesting that acute
hyperglycaemia may lead to impaired
cognitive performance and productivity, but
the relationship between these effects and daily
activities remains poorly understood. Further
research is required to enhance our
understanding of acute hyperglycaemia in
daily life. A better appreciation of clinically
relevant effects of acute hyperglycaemia will
allow us to determine whether it needs to be
addressed by specific treatment.
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